306 related articles for article (PubMed ID: 11716434)
1. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
[TBL] [Abstract][Full Text] [Related]
2. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
4. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Pommier Y; Orr A; Kohn KW; Riou JF
Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259
[TBL] [Abstract][Full Text] [Related]
6. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
[TBL] [Abstract][Full Text] [Related]
7. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Jensen PB; Sørensen BS; Sehested M; Grue P; Demant EJ; Hansen HH
Cancer Res; 1994 Jun; 54(11):2959-63. PubMed ID: 8187081
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.
Markovits J; Pommier Y; Kerrigan D; Covey JM; Tilchen EJ; Kohn KW
Cancer Res; 1987 Apr; 47(8):2050-5. PubMed ID: 3030540
[TBL] [Abstract][Full Text] [Related]
10. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
Barret JM; Calsou P; Larsen AK; Salles B
Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322
[TBL] [Abstract][Full Text] [Related]
11. Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase II.
Markovits J; Pommier Y; Mattern MR; Esnault C; Roques BP; Le Pecq JB; Kohn KW
Cancer Res; 1986 Nov; 46(11):5821-6. PubMed ID: 3019538
[TBL] [Abstract][Full Text] [Related]
12. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants.
Liu SY; Hwang BD; Haruna M; Imakura Y; Lee KH; Cheng YC
Mol Pharmacol; 1989 Jul; 36(1):78-82. PubMed ID: 2546053
[TBL] [Abstract][Full Text] [Related]
13. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Holm C; Covey JM; Kerrigan D; Pommier Y
Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of sulfonamide derivatives of epipodophyllotoxin.
Guianvarc'h D; Duca M; Boukarim C; Kraus-Berthier L; Léonce S; Pierré A; Pfeiffer B; Renard P; Arimondo PB; Monneret C; Dauzonne D
J Med Chem; 2004 Apr; 47(9):2365-74. PubMed ID: 15084135
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of 9-anilinoacridines as inhibitors of human DNA topoisomerase II.
Figgitt DP; Denny WA; Gamage SA; Ralph RK
Anticancer Drug Des; 1994 Jun; 9(3):199-208. PubMed ID: 8031452
[TBL] [Abstract][Full Text] [Related]
16. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
17. Linkage of a triple helix-forming oligonucleotide to amsacrine-4-carboxamide derivatives modulates the sequence-selectivity of topoisomerase II-mediated DNA cleavage.
Arimondo P; Bailly C; Boutorine A; Asseline U; Sun JS; Garestier T; Hélène C
Nucleosides Nucleotides Nucleic Acids; 2000 Aug; 19(8):1205-18. PubMed ID: 11097051
[TBL] [Abstract][Full Text] [Related]
18. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
Fry AM; Chresta CM; Davies SM; Walker MC; Harris AL; Hartley JA; Masters JR; Hickson ID
Cancer Res; 1991 Dec; 51(24):6592-5. PubMed ID: 1660343
[TBL] [Abstract][Full Text] [Related]
19. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
20. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
